Valneva, Sanofi deal
Valneva and Sanofi's Sanofi Pasteur vaccines division added a fourth mAb discovery program to a 2010 deal granting Sanofi Pasteur exclusive access to Valneva's VivaScreen technology to discover human mAbs to treat and prevent nosocomial infections and other infectious diseases. Sanofi Pasteur, which will provide research funding, will have exclusive, worldwide rights to develop and commercialize discovered antibodies under the deal. Valneva is eligible for up to €35 million ($48.1 million) per infectious disease, plus royalties. Valneva declined to disclose details, and Sanofi could not be reached. The deal was originally signed between Sanofi Pasteur and Vivalis S.A., which merged with Intercell AG in 2013 to form Valneva (see BioCentury, June 14, 2010 & Jan. 23, 2012). ...